Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $85
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Trade with 70% Backtested Accuracy
Analyst Views on MNPR
About MNPR
About the author
Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings
- Price Target Adjustment: Goldman Sachs has cut its price target for Netflix from $130 to $112, reflecting a cautious outlook ahead of the upcoming earnings report, which is expected to show solid performance by the end of 2025 as management executes its core strategic focus.
- Content Strategy: Goldman emphasizes that Netflix will continue to rely on original and returning original content to drive user engagement and growth, a strategy that may impact user retention and market share in the competitive streaming landscape.
- Market Expectations: While Goldman maintains a neutral rating on Netflix, the market's reaction to the forthcoming earnings report could lead to stock price volatility, particularly given the uncertainties in the macroeconomic environment.
- Competitive Pressure: Netflix faces competitive pressures from other streaming platforms, especially regarding content richness and user experience, which could affect its growth potential moving forward.
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
- Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
- Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
- FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
- Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.
Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925
- Insider Purchase: Monopar Therapeutics CFO Quan Anh Vu purchased 1,500 shares of MNPR at $69.95 each on Friday, totaling an investment of $104,925, indicating confidence in the company's future prospects.
- Market Reaction: Despite Vu's purchase signaling optimism about the company's outlook, MNPR's stock fell approximately 1.1% on Monday, reflecting market caution regarding the company's current situation.
- Purchase Frequency: This marks Vu's first stock purchase in the past 12 months, potentially indicating a reassessment of the company's value or expectations for future performance.
- Investor Confidence: Insider buying is generally viewed as a positive signal for the company's future, which may bolster confidence among other investors, even though the stock's short-term performance remains weak.
Home Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Analyst Downgrades: Several top Wall Street analysts have downgraded their ratings on various companies, including Gambling.com Group Ltd, Ardent Health Inc, Home Depot Inc, Flowserve Corp, and Monopar Therapeutics Inc.
Gambling.com Group Ltd: BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral, with shares closing at $5.25.
Ardent Health Inc: Morgan Stanley's Craig Hettenbach downgraded the rating from Overweight to Equal-Weight, reducing the price target from $22 to $12, with shares closing at $9.30.
Home Depot Inc: Stifel analyst W. Andrew Carter downgraded the stock from Buy to Hold, lowering the price target from $440 to $370, with shares closing at $368.07.
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $100
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: The platform is designed to help traders win in the markets every day by providing accurate and immediate stock market information.
Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings
- Price Target Adjustment: Goldman Sachs has cut its price target for Netflix from $130 to $112, reflecting a cautious outlook ahead of the upcoming earnings report, which is expected to show solid performance by the end of 2025 as management executes its core strategic focus.
- Content Strategy: Goldman emphasizes that Netflix will continue to rely on original and returning original content to drive user engagement and growth, a strategy that may impact user retention and market share in the competitive streaming landscape.
- Market Expectations: While Goldman maintains a neutral rating on Netflix, the market's reaction to the forthcoming earnings report could lead to stock price volatility, particularly given the uncertainties in the macroeconomic environment.
- Competitive Pressure: Netflix faces competitive pressures from other streaming platforms, especially regarding content richness and user experience, which could affect its growth potential moving forward.
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
- Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
- Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
- FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
- Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.
Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925
- Insider Purchase: Monopar Therapeutics CFO Quan Anh Vu purchased 1,500 shares of MNPR at $69.95 each on Friday, totaling an investment of $104,925, indicating confidence in the company's future prospects.
- Market Reaction: Despite Vu's purchase signaling optimism about the company's outlook, MNPR's stock fell approximately 1.1% on Monday, reflecting market caution regarding the company's current situation.
- Purchase Frequency: This marks Vu's first stock purchase in the past 12 months, potentially indicating a reassessment of the company's value or expectations for future performance.
- Investor Confidence: Insider buying is generally viewed as a positive signal for the company's future, which may bolster confidence among other investors, even though the stock's short-term performance remains weak.
Home Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday
Analyst Downgrades: Several top Wall Street analysts have downgraded their ratings on various companies, including Gambling.com Group Ltd, Ardent Health Inc, Home Depot Inc, Flowserve Corp, and Monopar Therapeutics Inc.
Gambling.com Group Ltd: BTIG analyst Clark Lampen downgraded the stock from Buy to Neutral, with shares closing at $5.25.
Ardent Health Inc: Morgan Stanley's Craig Hettenbach downgraded the rating from Overweight to Equal-Weight, reducing the price target from $22 to $12, with shares closing at $9.30.
Home Depot Inc: Stifel analyst W. Andrew Carter downgraded the stock from Buy to Hold, lowering the price target from $440 to $370, with shares closing at $368.07.
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.
Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.
Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $100
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, fostering a collaborative environment for sharing market intelligence.
Market Success: The platform is designed to help traders win in the markets every day by providing accurate and immediate stock market information.
